- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
CLS Holdings USA Buys Entry to Adult Market in Massachusetts
CLS Holdings USA earned a positive review after securing entry to the recreational cannabis market in Massachusetts, which legalized adult-use sales last year.
CLS Holdings USA (CSE:CLSH,OTCQB:CLSH) has completed a “major milestone,” in the eyes of one analyst, by securing a recreational marijuana state license holder in Massachusetts.
CLS has an option to acquire the license holder, In Good Health, a local medical dispensary based in Brockton. It received its recreational license for the state last Tuesday (September 17).
According to CLS, In Good Health currently serves over 25,000 enrolled patients and its entire operation could generate US$60 million in revenue a year, with gross profits of US$35 million.
In a statement, Jeff Binder, chairman and CEO of the public firm, said the license was one of the first to be handed out in the state. The executive added that he expects only 27 recreational licenses for retailers in Massachusetts, including the one for In Good Health.
The New England state launched sales of adult-use marijuana in November 2018.
CLS plans to roll out the sale of recreational cannabis products “in the coming weeks.”
“…We expect that In Good Health will quickly build a large and loyal customer base in the recreational cannabis market and become one of the larger recreational use dispensaries in the state,” Andrew Glashow, president and COO of CLS, said in a statement.
In a research note to investors, Canaccord Genuity praised the deal for CLS. However, the note indicates that the firm will most likely still need financial support to complete the acquisition of In Good Health.
Canaccord Genuity has a one year price target of C$1.50 for CLS. Shares of the US company opened on Monday (September 23) at a price of C$0.32.
The public firm expects to complete its acquisition of the cannabis company in January 2020.
According to data from Marijuana Business Daily, as of May, sales of recreational marijuana in the state had reached just under US$140 million in the aggregate since legalization.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.